Uj szerek és kihívások az arteriás betegségek antithromboticus kezelésében.

Translated title of the contribution: New agents and challenges in the antithrombotic management of arterial diseases

M. Udvardy, K. Rák

Research output: Contribution to journalArticle

Abstract

The past decades have exposed and faced antithrombotic therapy (anticoagulants, antiplatelet agents, and fibrinolytics) to new challenges. The reperfusion treatment modalities of myocardial infarction needed improvement of fibrinolytic agents and adjuvant anticoagulant-antiplatelet therapy. The secondary prevention of stroke, along with the renewal of thrombolytic and anticoagulant therapy seems to be an other major area of new approach to antithrombotic therapy. The reocclusion and restenosis of coronary arteries means the most difficult issue and task for antithrombotic treatment modalities. These requirements accelerated the development of novel antithrombotic agents, the disintegrin family, the monoclonals directed against platelet adhesion and aggregation, the application of hirudin and its analogs and new generation of thrombolytic agents. Combined and sequential administration of different antithrombotic agents receives growing attention and seems also to be promising.

Original languageHungarian
Pages (from-to)59-65
Number of pages7
JournalOrvosi Hetilap
Volume138
Issue number2
Publication statusPublished - Jan 12 1997

Fingerprint

Disease Management
Fibrinolytic Agents
Anticoagulants
Disintegrins
Hirudins
Therapeutics
Platelet Aggregation Inhibitors
Thrombolytic Therapy
Secondary Prevention
Platelet Aggregation
Reperfusion
Coronary Vessels
Stroke
Myocardial Infarction

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Uj szerek és kihívások az arteriás betegségek antithromboticus kezelésében. / Udvardy, M.; Rák, K.

In: Orvosi Hetilap, Vol. 138, No. 2, 12.01.1997, p. 59-65.

Research output: Contribution to journalArticle

@article{04f34de056754e46920aefc306fd9c47,
title = "Uj szerek {\'e}s kih{\'i}v{\'a}sok az arteri{\'a}s betegs{\'e}gek antithromboticus kezel{\'e}s{\'e}ben.",
abstract = "The past decades have exposed and faced antithrombotic therapy (anticoagulants, antiplatelet agents, and fibrinolytics) to new challenges. The reperfusion treatment modalities of myocardial infarction needed improvement of fibrinolytic agents and adjuvant anticoagulant-antiplatelet therapy. The secondary prevention of stroke, along with the renewal of thrombolytic and anticoagulant therapy seems to be an other major area of new approach to antithrombotic therapy. The reocclusion and restenosis of coronary arteries means the most difficult issue and task for antithrombotic treatment modalities. These requirements accelerated the development of novel antithrombotic agents, the disintegrin family, the monoclonals directed against platelet adhesion and aggregation, the application of hirudin and its analogs and new generation of thrombolytic agents. Combined and sequential administration of different antithrombotic agents receives growing attention and seems also to be promising.",
author = "M. Udvardy and K. R{\'a}k",
year = "1997",
month = "1",
day = "12",
language = "Hungarian",
volume = "138",
pages = "59--65",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "2",

}

TY - JOUR

T1 - Uj szerek és kihívások az arteriás betegségek antithromboticus kezelésében.

AU - Udvardy, M.

AU - Rák, K.

PY - 1997/1/12

Y1 - 1997/1/12

N2 - The past decades have exposed and faced antithrombotic therapy (anticoagulants, antiplatelet agents, and fibrinolytics) to new challenges. The reperfusion treatment modalities of myocardial infarction needed improvement of fibrinolytic agents and adjuvant anticoagulant-antiplatelet therapy. The secondary prevention of stroke, along with the renewal of thrombolytic and anticoagulant therapy seems to be an other major area of new approach to antithrombotic therapy. The reocclusion and restenosis of coronary arteries means the most difficult issue and task for antithrombotic treatment modalities. These requirements accelerated the development of novel antithrombotic agents, the disintegrin family, the monoclonals directed against platelet adhesion and aggregation, the application of hirudin and its analogs and new generation of thrombolytic agents. Combined and sequential administration of different antithrombotic agents receives growing attention and seems also to be promising.

AB - The past decades have exposed and faced antithrombotic therapy (anticoagulants, antiplatelet agents, and fibrinolytics) to new challenges. The reperfusion treatment modalities of myocardial infarction needed improvement of fibrinolytic agents and adjuvant anticoagulant-antiplatelet therapy. The secondary prevention of stroke, along with the renewal of thrombolytic and anticoagulant therapy seems to be an other major area of new approach to antithrombotic therapy. The reocclusion and restenosis of coronary arteries means the most difficult issue and task for antithrombotic treatment modalities. These requirements accelerated the development of novel antithrombotic agents, the disintegrin family, the monoclonals directed against platelet adhesion and aggregation, the application of hirudin and its analogs and new generation of thrombolytic agents. Combined and sequential administration of different antithrombotic agents receives growing attention and seems also to be promising.

UR - http://www.scopus.com/inward/record.url?scp=19244377825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19244377825&partnerID=8YFLogxK

M3 - Article

VL - 138

SP - 59

EP - 65

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 2

ER -